Bangi, 6 February 2025 – The ¼¯ÃÀÂ鶹 Technology Commercialization Ceremony for Dermal Fibroblast Sera, a collaboration between INOVASI@¼¯ÃÀÂ鶹 and F2 Bio Sdn. Bhd., was successfully held at the CRIM Workshop Room, ¼¯ÃÀÂ鶹.
The event was attended by representatives from ¼¯ÃÀÂ鶹, including Assoc. Prof. Dr. Wan Mohd Hirwani Wan Hussain, Director of INOVASI@¼¯ÃÀÂ鶹, and Prof. Dr. Sawal Hamid Md Ali, Deputy Director of INOVASI@¼¯ÃÀÂ鶹. Meanwhile, F2 Bio Sdn. Bhd. was represented by Dr. Zhou Fang, the company’s Director, along with Mr. Jason W.Y. Woo.
Under this agreement, F2 Bio Sdn. Bhd. has been granted exclusive rights to manufacture, package, distribute, and market Dermal Fibroblast Sera, a cutting-edge cosmetic product developed by a research team from the Centre for Tissue Engineering & Regenerative Medicine (CTERM), Faculty of Medicine, ¼¯ÃÀÂ鶹, led by Assoc. Prof. Dr. Angela Ng Min Hwei.
Science-Based Technology for the Beauty Industry
Dermal Fibroblast Sera utilizes a specialized keratinocyte medium to stimulate skin regeneration, offering a scientific solution to slow down skin aging.
This event marks a significant milestone in ¼¯ÃÀÂ鶹’s efforts to commercialize its research innovations, further strengthening strategic collaborations between academia and industry. With high confidence in the potential of this technology, ¼¯ÃÀÂ鶹 and F2 Bio Sdn. Bhd. plan to expand into international markets and explore medical applications for the product.
This partnership reflects ¼¯ÃÀÂ鶹’s commitment to positioning innovation as a key driver of industry advancement, ultimately benefiting society as a whole.